PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-5.73%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.82%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.05%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-5.05%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3274.19%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-3274.19%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.86%
10Y OCF/share CAGR at 50-75% of GNPX's 91.62%. Martin Whitman might fear a structural deficiency in operational efficiency.
47.86%
Below 50% of GNPX's 96.48%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
47.86%
3Y OCF/share CAGR under 50% of GNPX's 96.26%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
60.77%
Net income/share CAGR at 50-75% of GNPX's 99.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
60.77%
5Y net income/share CAGR at 50-75% of GNPX's 96.58%. Martin Whitman might see a shortfall in operational efficiency or brand power.
60.77%
3Y net income/share CAGR 50-75% of GNPX's 96.48%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.11%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.64%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
8.65%
Debt growth of 8.65% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
6.08%
SG&A declining or stable vs. GNPX's 52.68%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.